FDA Label Guidelines for Biologics: A Practical Reference

By Dr. Zubair Khalid, DVM, MS, PhD ·

FDA Label Guidelines for Biologics: A Practical Reference

Introduction to FDA Labeling Requirements for Biologics

The labeling of biological products—therapeutic proteins, monoclonal antibodies, vaccines, gene therapies, and cellular products—is governed by a regulatory framework that overlaps with, but is distinct from, that applied to small molecule drugs. The FDA treats the label as a summary of the evidence supporting the product's safety and effectiveness, and for biologics, the label carries additional weight because the product's inherent complexity—glycosylation patterns, three-dimensional conformation, immunogenic potential—cannot be fully captured by chemical characterization alone. The label is the single document that communicates to prescribers what the product is, what it does, and under what conditions it should be used.

The scope of FDA labeling regulations for biologics derives from two principal sources: the Federal Food, Drug, and Cosmetic Act (FD&C Act), which governs all drugs, and the Public Health Service Act (PHS Act), which governs biological products. The implementing regulations appear in Title 21 of the Code of Federal Regulations (CFR). For drug labeling generally, 21 CFR Part 201 sets forth content and format requirements. For biologics specifically, 21 CFR Part 601 addresses licensing provisions, including labeling requirements under §601.2(a) and §601.14. The practical effect is that a biologic's label must satisfy both the general drug labeling rules and the biologic-specific requirements.

Regulatory Basis: 21 CFR 201 and 21 CFR 601

21 CFR 201.56 and 201.57 establish the Physician Labeling Rule (PLR) format, which applies to all prescription drugs and biologics submitted for approval after June 30, 2001, and to all products being converted to the PLR format. The PLR format mandates a specific order and structure for the prescribing information (PI), designed to make labels more readable and clinically actionable. For biologics, 21 CFR 601.14 requires that the labeling include the statement "Manufactured by" or "Distributed by" with the applicable name and address, and it requires that the label not be false or misleading in any particular.

The PHS Act adds a layer of authority that the FD&C Act does not provide for small molecules: under §351 of the PHS Act, a biologic license is granted only upon a demonstration that the product is "safe, pure, and potent." The label must reflect these attributes. Potency, for instance, is typically expressed in units of biological activity, not mass, and the label must state the potency in a manner that is meaningful to the clinician. For a monoclonal antibody, this might be expressed as mg/mL with a defined binding activity; for a vaccine, it might be expressed as antigen content per dose.

Key FDA Guidance Documents for Biologic Labeling

The FDA has issued several guidance documents that directly address biologic labeling. The most relevant include:

  • "Labeling for Human Prescription Drug and Biological Products — Implementing the PLR Content and Format Requirements" (February 2006): This guidance provides the detailed structure for the PI, including the Highlights section, Table of Contents, and Full Prescribing Information sections 1 through 17.
  • "Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009" (April 2015, revised): This guidance addresses labeling considerations for biosimilar and interchangeable products, including the requirement that the label not imply that the biosimilar is a different product from the reference biologic.
  • "Immunogenicity Assessment for Therapeutic Protein Products" (August 2014): This guidance outlines the data needed to support the immunogenicity section of the label.
  • "Safety Considerations for Product Design to Minimize Medication Errors" (December 2016): This guidance addresses labeling elements that reduce the risk of medication errors, including the proper use of established names, strengths, and dosage forms.

For a broader overview of the regulatory landscape, see the FDA Regulations for Biologics reference, which covers the full scope of statutory and regulatory authority.

Structure and Content of the Prescribing Information (PI)

The PI for a biologic is organized according to the PLR format, which divides the label into three major components: Highlights of Prescribing Information, the Full Prescribing Information (sections 1 through 17), and, when required, a Medication Guide. The PLR format was designed to improve the usability of prescribing information by placing the most critical information at the front and using a standardized structure that clinicians can navigate quickly.

Highlights of Prescribing Information

The Highlights section is a concise summary of the most important information in the Full Prescribing Information. It is limited to approximately half a page and must include the following elements in order:

  1. Product name and initial U.S. approval date — The proprietary name, established name, and the date of initial licensure.
  2. Boxed Warning — If applicable, the most serious safety information, limited to a maximum of 20 lines.
  3. Recent Major Changes — A list of substantive changes made in the past 12 months, with section references.
  4. Indications and Usage — A brief statement of the approved indications.
  5. Dosage and Administration — The recommended dose, schedule, and route of administration.
  6. Dosage Forms and Strengths — The available presentations.
  7. Contraindications — Conditions under which the product should not be used.
  8. Warnings and Precautions — The most clinically significant safety concerns.
  9. Adverse Reactions — The most common and clinically significant adverse reactions.
  10. Use in Specific Populations — Key information for pregnancy, lactation, pediatric, and geriatric use.
  11. Patient Counseling Information — A cross-reference to the Medication Guide if one exists.

The Highlights section must include a statement that the label omits information essential for safe and effective use, directing the reader to the Full Prescribing Information. This is not boilerplate; it is a regulatory requirement that prevents the Highlights from being used as a standalone document.

Full Prescribing Information: Sections 1-17

The Full Prescribing Information is the complete, detailed label. The PLR format mandates the following section order:

  1. Indications and Usage — The specific conditions for which the product is approved, including any limitations of use.
  2. Dosage and Administration — Recommended doses, dosing schedules, dose adjustments for special populations, preparation instructions, and administration details.
  3. Dosage Forms and Strengths — The available formulations, including concentration, volume, and delivery system.
  4. Contraindications — Absolute prohibitions on use.
  5. Warnings and Precautions — Clinically significant safety concerns, including management of adverse reactions.
  6. Adverse Reactions — A summary of adverse reactions observed in clinical trials, with incidence rates.
  7. Drug Interactions — Clinically meaningful interactions with other drugs.
  8. Use in Specific Populations — Pregnancy, lactation, pediatric, geriatric, renal impairment, hepatic impairment.
  9. Drug Abuse and Dependence — Required only if the product has abuse potential; for most biologics, this section is a statement that the product is not a controlled substance.
  10. Overdosage — Information on management of overdose, if applicable.
  11. Description — The structural formula, physicochemical properties, and, for biologics, a description of the manufacturing process and the biological activity.
  12. Clinical Pharmacology — Mechanism of action, pharmacodynamics, pharmacokinetics, and immunogenicity.
  13. Nonclinical Toxicology — Carcinogenesis, mutagenesis, impairment of fertility, and animal toxicology studies.
  14. Clinical Studies — A summary of the clinical trials that established efficacy and safety.
  15. References — A list of published literature cited in the label.
  16. How Supplied/Storage and Handling — The available presentations, storage conditions, and handling instructions.
  17. Patient Counseling Information — Information to be communicated to patients.

For biologics, sections 11 (Description) and 12 (Clinical Pharmacology) are particularly important. The Description section must include the molecular structure, the cell line used for production, and the purification process in sufficient detail to distinguish the product from other biologics. The Clinical Pharmacology section must include immunogenicity data, which is discussed in detail below.

Medication Guides and Patient Information

A Medication Guide is required when the FDA determines that the product's labeling alone is insufficient to ensure safe use. This determination is made on a case-by-case basis, typically when the product has serious risks that require specific patient awareness or when patient adherence to specific instructions is critical. For biologics, Medication Guides are commonly required for products with significant immunosuppressive effects, products with a risk of serious infection, or products administered by patients at home.

The Medication Guide is written in non-technical language and must be dispensed with each prescription. It is not a substitute for the PI; rather, it is a patient-facing document that complements the PI. The FDA reviews the Medication Guide as part of the labeling review process, and it must be submitted with the Biologics License Application (BLA). For a detailed walkthrough of the BLA process, see the Biologics License Application FDA reference.

Specific Labeling Considerations for Biologics

Biologics present labeling challenges that do not arise for small molecule drugs. The inherent variability of biological products, the potential for immunogenicity, and the complexity of manufacturing all require specific labeling elements.

Biosimilar and Interchangeable Designations

The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) created an abbreviated licensure pathway for biosimilar and interchangeable biological products. The labeling of these products must comply with specific requirements that distinguish them from reference biologics.

A biosimilar product's label must include the same indications, dosage forms, strengths, and route of administration as the reference product. However, the label must not imply that the biosimilar is a different product or that it has characteristics that differ from the reference product. The FDA has stated that the label for a biosimilar should include a statement that the product is a biosimilar of the reference product, but the format of this statement is not prescribed by regulation. In practice, the label typically states: "This product is a biosimilar to [reference product]."

An interchangeable product, which may be substituted for the reference product without prescriber intervention, must include a statement of interchangeability. The label for an interchangeable product states: "This product is interchangeable with [reference product] for the indications listed in this label." The FDA requires that the interchangeability statement be prominently displayed, typically in the Highlights section.

The key distinction is that the biosimilar label cannot include data that are not in the reference product's label, even if the biosimilar sponsor generated additional clinical data. This is because the FDA considers the reference product's label to be the basis for the biosimilar's labeling, and any additional claims would require a separate demonstration of clinical benefit.

Immunogenicity Section

The immunogenicity section, typically located in section 12.6 of the Clinical Pharmacology portion of the PI, must present data on the incidence and clinical impact of anti-drug antibodies (ADAs). The FDA requires that this section include:

  • The incidence of ADA development, expressed as a percentage of treated patients.
  • The assay used to detect ADAs, including the assay format (e.g., bridging ELISA, cell-based assay) and the sensitivity of the assay.
  • The clinical consequences of ADA development, including effects on efficacy, safety, and pharmacokinetics.
  • The neutralizing antibody status, if measured.

The immunogenicity section must be written with care to avoid overstating or understating the risk. For example, if 15% of patients in clinical trials developed ADAs but only 2% had neutralizing antibodies, the label should state both figures and describe the clinical impact of each. The FDA also requires that the immunogenicity section include a statement about the limitations of the immunogenicity data, such as the fact that the assay used in clinical trials may not be directly comparable to assays used in postmarketing studies.

The data supporting the immunogenicity section must come from validated assays, and the FDA expects that the assay methodology will be described in sufficient detail to allow a reader to understand the strengths and limitations of the data. For a comprehensive discussion of the data requirements, see the FDA Guidance for Industry Biologics reference.

Storage and Handling Instructions

The storage and handling section (section 16) must provide specific, actionable instructions for the storage, preparation, and administration of the product. For biologics, this section is critical because improper storage can render the product ineffective or unsafe.

The FDA requires that the label state:

  • The recommended storage temperature (e.g., 2°C to 8°C for most monoclonal antibodies).
  • The stability of the product under various conditions, including room temperature excursions, if known.
  • The instructions for preparation, including dilution, mixing, and reconstitution steps.
  • The compatibility with common intravenous solutions, if applicable.
  • The instructions for protection from light, if required.
  • The expiration date and the dating period after first puncture or dilution.

For products that require reconstitution, the label must specify the diluent, the volume of diluent, the concentration of the final solution, and the stability of the reconstituted product. For example, a lyophilized monoclonal antibody might require reconstitution with 10 mL of sterile water for injection to yield a concentration of 25 mg/mL, with a statement that the reconstituted solution is stable for 24 hours at 2°C to 8°C.

The storage and handling section must also include a statement about the product's sensitivity to freezing, shaking, or other physical stress. For example, many monoclonal antibodies must not be frozen, and the label must state this explicitly.

Data Requirements to Support Labeling Claims

Every statement in the label must be supported by data that are included in the BLA. The FDA reviews the label against the data to ensure that no claim exceeds the evidence. The type and quality of data required depend on the nature of the claim.

Clinical Trial Data and Statistical Considerations

Efficacy claims in the Indications and Usage section must be supported by adequate and well-controlled clinical trials. The FDA expects that the primary efficacy endpoint will be clinically meaningful and that the statistical analysis will be pre-specified. For biologics, the FDA often requires that the primary endpoint be a measure of clinical benefit, not a surrogate endpoint, unless the surrogate has been validated.

The Clinical Studies section (section 14) must summarize the key trials that support the indication. This summary should include:

  • The study design (randomized, double-blind, placebo-controlled, active-controlled).
  • The patient population, including inclusion and exclusion criteria.
  • The primary and secondary endpoints.
  • The treatment groups and sample sizes.
  • The duration of treatment and follow-up.
  • The key efficacy results, including effect sizes and confidence intervals.
  • The key safety results, including adverse events and laboratory abnormalities.

The FDA requires that the label present the results in a balanced manner. If the treatment effect is modest or the confidence interval is wide, the label must reflect this uncertainty. The FDA also requires that the label include the number needed to treat (NNT) or number needed to harm (NNH) when these are clinically meaningful, although this is not a universal requirement.

Pharmacokinetic and Pharmacodynamic Data

The Clinical Pharmacology section (section 12) must include pharmacokinetic (PK) and pharmacodynamic (PD) data that support the dosing recommendations. For biologics, the PK data must address:

  • The absorption, distribution, metabolism, and excretion (ADME) of the product.
  • The effect of dose and route of administration on exposure.
  • The impact of patient characteristics (age, sex, renal function, hepatic function) on PK.
  • The potential for drug-drug interactions, particularly with other biologics or immunosuppressants.
  • The relationship between exposure and response, if known.

For monoclonal antibodies, the PK profile is characterized by a long half-life (typically 2 to 4 weeks), low clearance, and limited distribution into tissues. The label must state the observed half-life, the volume of distribution, and the clearance, with appropriate units. The PD data must describe the relationship between dose and pharmacologic effect, such as receptor occupancy or cytokine levels.

The FDA expects that the PK and PD data will be presented in a format that is accessible to clinicians. This means that the label should state the typical steady-state concentrations, the time to reach steady state, and the impact of dose adjustments on exposure.

Postmarketing Data and Label Updates

Postmarketing data play a critical role in maintaining the accuracy of the label. The FDA requires that sponsors monitor the safety of their products after approval and report adverse events, and the agency may require that the label be updated to reflect new safety information.

The types of postmarketing data that can lead to label changes include:

  • New adverse events not observed in clinical trials.
  • Changes in the frequency or severity of known adverse events.
  • New drug interactions identified through pharmacovigilance.
  • New efficacy data from postmarketing studies.
  • New immunogenicity data from postmarketing studies.

The FDA distinguishes between labeling changes that require prior approval (PAS), changes that can be implemented before approval (CBE), and changes that can be reported in an annual report. The specific requirements are discussed in the section on post-approval labeling changes below.

The Labeling Review Process at FDA

The labeling review is an integral part of the BLA review process. The FDA reviews the proposed labeling concurrently with the clinical and nonclinical data to ensure that the label accurately reflects the evidence.

Submission of Proposed Labeling

The proposed labeling is submitted as part of the BLA, typically in Module 1 of the electronic Common Technical Document (eCTD). The submission must include:

  • The proposed PI in PLR format.
  • The proposed Medication Guide, if required.
  • The proposed carton and container labels.
  • A labeling review checklist, if requested by the FDA.

The FDA recommends that sponsors submit the proposed labeling early in the review process, ideally with the original BLA submission. This allows the review team to identify labeling issues early and to provide feedback before the end of the review cycle.

FDA Review and Comment Cycles

The labeling review is conducted by the review division within the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER), depending on the product. The review team includes:

  • The regulatory project manager, who coordinates the review.
  • The medical officer, who reviews the clinical data and the efficacy and safety claims.
  • The clinical pharmacologist, who reviews the PK/PD data and the dosing recommendations.
  • The statistician, who reviews the statistical analyses.
  • The pharmacovigilance reviewer, who assesses the safety data.
  • The labeling reviewer, who ensures that the label meets the PLR format requirements.

The Office of Prescription Drug Promotion (OPDP) reviews the label to ensure that it is not false or misleading and that it complies with the regulations on promotional labeling. The Division of Medication Error Prevention and Analysis (DMEPA) reviews the label to identify potential sources of medication errors, such as confusing drug names, ambiguous dosing instructions, or unclear storage requirements.

The FDA typically provides comments on the proposed labeling in the form of a labeling comment letter, which is issued during the review cycle. The sponsor must respond to the comments, either by revising the label or by providing justification for the proposed language. This negotiation process can take several rounds, and it is common for the label to change substantially between the initial submission and the final approval.

Labeling Negotiation and Final Approval

The final labeling is negotiated between the sponsor and the FDA during the late stages of the review. The FDA issues a "labeling negotiation" letter that includes the agency's proposed language for each section of the label. The sponsor must either accept the FDA's language or provide a written justification for alternative language.

The FDA has the authority to approve the BLA with labeling that differs from the sponsor's proposed labeling. In practice, the FDA and the sponsor work collaboratively to reach an agreement, but the FDA has the final say. The approved labeling is posted on the FDA's website, and the sponsor must use the approved labeling in the commercial packaging.

For a detailed timeline of the BLA review process, see the FDA Approval Process for Biologics reference.

Common Pitfalls in Biologic Labeling

Drafting a biologic label is a complex task, and even experienced regulatory professionals make errors. The following are the most common pitfalls observed in BLA submissions.

Overstating Benefits or Minimizing Risks

The most common labeling error is overstating the efficacy of the product or minimizing the risks. This can occur in several ways:

  • Using absolute risk reduction instead of relative risk reduction when the absolute effect is small.
  • Emphasizing secondary endpoints when the primary endpoint was not met.
  • Omitting adverse events that occurred at a low frequency but are clinically significant.
  • Using language that implies a causal relationship when the data only support an association.

The FDA is particularly vigilant about the use of superlatives in the label. Words like "safe," "effective," "well-tolerated," and "potent" are considered promotional, not informative, and are generally not permitted in the label. The label should state the facts—the incidence of adverse events, the magnitude of the treatment effect—and let the reader draw conclusions.

Inconsistent Terminology

Biologic labels are reviewed by multiple disciplines, and inconsistent terminology can create confusion. Common examples include:

  • Using different terms for the same adverse event (e.g., "injection site reaction" in one section and "local reaction" in another).
  • Using different units for the same parameter (e.g., mg/mL in one section and mg/L in another).
  • Using different names for the same product (e.g., the proprietary name in the Highlights and the established name in the Description).

The FDA requires that the label use consistent terminology throughout. The established name should be used consistently, and the proprietary name should appear only in the Highlights and the How Supplied section.

Incomplete Storage or Handling Information

The storage and handling section is a common source of FDA comments. Sponsors often omit critical information, such as:

  • The stability of the product after dilution or reconstitution.
  • The compatibility with specific infusion sets or pumps.
  • The instructions for protecting the product from light.
  • The behavior of the product if accidentally frozen or shaken.

The FDA expects that the storage and handling section will be complete and actionable. If the product is a lyophilized powder, the label must state the exact reconstitution procedure, including the diluent, the volume, the mixing technique, and the stability of the reconstituted solution. If the product is a liquid, the label must state whether it can be frozen, whether it must be protected from light, and whether it can be shaken.

Post-Approval Labeling Changes and Maintenance

The label is not a static document. After approval, the sponsor must update the label to reflect new safety and efficacy data. The FDA has established a framework for labeling changes that balances the need for timely updates with the need for regulatory oversight.

Types of Labeling Changes

The FDA categorizes labeling changes into three types, based on the level of review required:

  1. Prior Approval Supplement (PAS): Changes that require FDA approval before implementation. These include changes to the Indications and Usage, Dosage and Administration, Contraindications, and Warnings and Precautions sections. A PAS must be submitted and approved before the sponsor can distribute the revised label.
  1. Changes Being Effected (CBE): Changes that can be implemented before FDA approval, but must be submitted as a supplement at the time of implementation. CBE changes include additions to the Adverse Reactions section, updates to the Patient Counseling Information, and changes to the storage and handling instructions that do not affect the safety or effectiveness of the product. There are two subcategories: CBE-0, which can be implemented immediately, and CBE-30, which requires 30 days' notice before implementation.
  1. Annual Report (AR): Changes that can be implemented immediately and reported in the annual report. These include minor editorial changes, updates to the manufacturer's name and address, and changes to the packaging that do not affect the label content.

The specific requirements for each type of change are detailed in the FDA Post Approval Changes Guidance Biologics reference.

Submission Requirements and Timelines

The submission requirements for a labeling change depend on the type of change. A PAS must include the proposed revised label, a description of the change, and the data supporting the change. The FDA has 180 days to review a PAS, although the review clock can be extended if the agency requests additional information.

A CBE supplement must include the proposed revised label and a description of the change, but the sponsor can implement the change immediately (for CBE-0) or after 30 days (for CBE-30). The FDA reviews the CBE supplement after implementation and may require the sponsor to revise the label if the change is not acceptable.

An annual report must include a summary of all changes made during the year, including labeling changes. The FDA reviews the annual report and may request additional information or require that a change be submitted as a PAS or CBE if the agency disagrees with the categorization.

The sponsor is responsible for ensuring that the label is updated in a timely manner. The FDA does not proactively update labels; it relies on the sponsor to submit the necessary supplements. Failure to update the label can result in the product being considered misbranded, which is a violation of the FD&C Act.

Practical Summary and Best Practices for Biologic Labeling

The following best practices are derived from the FDA's guidance documents and from the experience of successful BLA submissions.

Start early. Begin drafting the label during the clinical development program, not after the BLA is complete. The label should be a living document that evolves as data accumulate.

Use the PLR format from the beginning. Do not draft the label in a non-PLR format and then convert it later. The PLR format is the standard, and drafting in the correct format from the start reduces the risk of errors.

Be precise about the data. Every claim in the label must be traceable to a specific data table in the BLA. If the data do not support a claim, remove the claim.

Anticipate FDA comments. The FDA will comment on the label, and many of the comments will be predictable. Review the FDA's guidance documents and the labels of approved products in the same therapeutic area to identify common issues.

Involve the right people. The label should be reviewed by the medical officer, the clinical pharmacologist, the statistician, and the regulatory affairs professional. Each brings a different perspective, and the label is stronger when all perspectives are considered.

Plan for post-approval changes. The label will need to be updated after approval. Establish a process for monitoring safety data, reviewing the label, and submitting the appropriate supplements.

For a broader perspective on the development of biologics, see the Biologics Development reference, and for a historical overview of approved products, see the FDA Approved Biologics by Year reference.

Frequently Asked Questions

What is the Physician Labeling Rule (PLR) and how does it apply to biologics?

The Physician Labeling Rule (PLR) is a regulatory framework established by the FDA in 2006 that mandates a standardized format for the prescribing information of prescription drugs and biologics. The PLR format requires that the label be organized into three components: Highlights of Prescribing Information, Full Prescribing Information (sections 1 through 17), and, when required, a Medication Guide. The PLR applies to all biologics approved after June 30, 2001, and to all products being converted to the PLR format. The goal of the PLR is to improve the usability of the label by placing the most critical information at the front and using a consistent structure across all products.

How are biosimilar products labeled differently from reference biologics?

Biosimilar products are labeled with the same indications, dosage forms, strengths, and route of administration as the reference product. However, the label must include a statement that the product is a biosimilar of the reference product. The label cannot include data that are not in the reference product's label, even if the biosimilar sponsor generated additional clinical data. For interchangeable products, the label must include a statement of interchangeability, indicating that the product can be substituted for the reference product without prescriber intervention.

What information must be included in the immunogenicity section of a biologic label?

The immunogenicity section, typically located in section 12.6 of the Clinical Pharmacology portion of the PI, must include the incidence of anti-drug antibodies (ADAs), the assay used to detect ADAs, the clinical consequences of ADA development, and the neutralizing antibody status. The section must also include a statement about the limitations of the immunogenicity data, such as the fact that the assay used in clinical trials may not be directly comparable to assays used in postmarketing studies.

Can a biologic label include off-label uses?

No. The label can only include indications that have been approved by the FDA. Off-label uses—uses that are not approved by the FDA—cannot be included in the label. The FDA prohibits the promotion of off-label uses, and including off-label uses in the label would render the product misbranded.

What are the common reasons for FDA rejection of a proposed biologic label?

The most common reasons for FDA rejection of a proposed label are overstating the efficacy of the product, minimizing the risks, using inconsistent terminology, and providing incomplete storage or handling information. The FDA also rejects labels that use promotional language, such as "safe" or "effective," and labels that do not comply with the PLR format.

How often must a biologic label be updated?

There is no fixed schedule for label updates. The label must be updated whenever new safety or efficacy data become available that affect the product's benefit-risk profile. The FDA requires that sponsors monitor the safety of their products after approval and submit labeling changes as needed. The frequency of updates depends on the product and the data.

What is the role of the Medication Guide for biologics?

The Medication Guide is a patient-facing document that is required when the FDA determines that the product's labeling alone is insufficient to ensure safe use. The Medication Guide is written in non-technical language and must be dispensed with each prescription. It is not a substitute for the PI; rather, it is a complement that provides patients with the information they need to use the product safely.

Key Takeaways

  • The FDA label for a biologic is a regulatory document that must accurately reflect the evidence supporting the product's safety and effectiveness, and it must comply with the PLR format.
  • The label is reviewed by multiple FDA offices, including the medical review team, OPDP, and DMEPA, and the sponsor must be prepared to negotiate the final language.
  • Biosimilar and interchangeable products have specific labeling requirements that distinguish them from reference biologics.
  • The immunogenicity section must present data on the incidence and clinical impact of anti-drug antibodies, with a clear description of the assay methodology.
  • Storage and handling instructions must be complete and actionable, including specific temperatures, diluents, and stability statements.
  • Post-approval labeling changes are categorized as PAS, CBE, or annual report changes, and the sponsor must submit the appropriate supplement in a timely manner.
  • The most common labeling pitfalls are overstating benefits, minimizing risks, using inconsistent terminology, and providing incomplete storage information; these can be avoided by starting early, using the PLR format, and involving the right people in the drafting process.

Related Clinical & Scientific Guides